APX3330: End-of-Phase 2 meeting scheduled with FDA to confirm Phase 3 regulatory path for oral APX3330 in DR Q4 2023; Nyxol: PDUFA date for Nyxol in RM September 28, 2023. FDA approval in RM would trigger a $10 million milestone payment to Ocuphire. Nyxol: Topline results from VEGA-2 Phase 3 pivotal trial of Nyxol in Presbyopia Q4 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCUP:
- Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
- Is OCUP a Buy, Before Earnings?
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Ocuphire Pharma schedules End-of-Phase 2 meeting with FDA for APX3330
- Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
